MedTrace Logo

Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator

NCT00175435 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2010-11-02

No results posted yet for this study

Summary

This study will look at what happens to the level of protection against hepatitis B (HB) disease if a 'helper' gel is applied to the skin over the injection site of a small dose of hepatitis B vaccine.

Conditions

Interventions

BIOLOGICAL

Resiquimod gel

3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator

BIOLOGICAL

Resiquimod gel

3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.

BIOLOGICAL

Resiquimod gel

3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Jan Dutz, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00175435 on ClinicalTrials.gov